| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18442 R78270 |
Lee (Controls exposed to TCAs), 2025 | Postpartum haemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SSRI only |
1.63 [1.03;2.57] C excluded (control group) |
91/1,465 24/613 | 115 | 1,465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18408 R77692 |
Lee (Controls unexposed, general pop), 2025 | Postpartum haemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: SSRI only | 1.19 [0.95;1.49] | 91/1,465 19,755/463,440 | 19,846 | 1,465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17719 R74736 |
Jackson, 2024 | Post-partum hemorrhage (ICD-10 diagnosis code for PPH and a procedure code for blood transfusion) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free | Adjustment: Yes Monotherapy: SSRI only | 1.59 [1.24;2.00] | 84/2,106 3,047/105,000 | 3,131 | 2,106 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7914 R23953 |
Palmsten, 2020 | Postpartum haemorrhage (PPH) within 14 days after delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Monotherapy: SSRI only Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.20 [0.96;1.50] C | 149/3,636 170/4,949 | 319 | 3,636 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7473 R22365 |
Skalkidou (Controls unexposed, disease free), 2020 | Postpartum haemorrhage (blood loss >1000 ml during the first 2 hours postpartum) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes Monotherapy: no or not specified |
1.33 [1.23;1.44] excluded (control group) |
781/8,551 18,520/265,080 | 19,301 | 8,551 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7829 R23243 |
Skalkidou (Controls unexposed, sick), 2020 | Postpartum haemorrhage (blood loss >1000 ml during the first 2 hours postpartum) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Monotherapy: no or not specified Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified | 1.23 [1.13;1.34] C | 781/8,551 2,150/28,390 | 2,931 | 8,551 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7604 R22715 |
Hanley, 2016 | Postpartum hemorrhage | late pregnancy | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: SSRI only | 1.07 [0.97;1.18] | 486/6,637 21,745/310,813 | 22,231 | 6,637 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7599 R23916 |
Lupattelli (Controls unexposed, disease free), 2014 | Postpartum hemorrhage (blood loss greater than 500 mL) | late pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: Yes Monotherapy: SSRI only |
0.97 [0.57;1.65] excluded (control group) |
18/123 8,009/55,862 | 8,027 | 123 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7902 R23925 |
Lupattelli (Controls unexposed, sick), 2014 | Postpartum hemorrhage (blood loss greater than 500 mL) | late pregnancy | prospective cohort | unexposed, sick | Adjustment: No Monotherapy: SSRI only Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 0.87 [0.52;1.47] C | 18/123 211/1,282 | 229 | 123 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7602 R23860 |
Palmsten b, 2013 | Postpartum hemorrhage (ICD-9 code for 666.x) | late pregnancy | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: SSRI only Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified | 1.42 [1.27;1.57] | 440/11,516 1,896/69,044 | 2,336 | 11,516 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S493 R15215 |
Colvin, 2011 | Postpartum hemorrhage (>= 500 mls) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 1.21 [1.09;1.35] | 400/3,703 8,462/92,995 | 8,862 | 3,703 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7601 R23861 |
Salkeld, 2008 | Postpartum hemorrhage (diagnosis codes 666.10, 666.12, and 666.14 (ICD-9), codes O72002, O72004, O72102, O72104, O72109, O72202, O72204, or O72209 (ICD-10)) after vaginal or cesarean delivery | 3rd trimester | nested case control | unexposed (general population or NOS) | Adjustment: Yes Matched Monotherapy: no or not specified | 1.30 [0.98;1.72] | 59/501 2,401/25,902 | 2,460 | 501 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 9 studies | 1.24 [1.14;1.35] | 62,345 | 38,238 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop; 2: Controls unexposed, sick; 3: Controls unexposed, sick;
Asymetry test p-value = 0.8784 (by Egger's regression)
slope=0.1930 (0.0886); intercept=0.2034 (1.2820); t=0.1587; p=0.8784
excluded 7599, 7473, 18442